Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 March 2024, including: Galderma S.A. prepares to take on Dupixent; Pfizer Inc.’s plans for Adcetris in DLBCL; Eli Lilly and Company’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with Bristol Myers Squibb Company’s CDTO Greg Meyers.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent" - Scrip, 11 Mar, 2024.)
(Also see "In Competitive DLBCL Setting, Pfizer Goes Old School With Adcetris" - Scrip, 12 Mar, 2024.)
(Also see "Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again" - Scrip, 8 Mar, 2024.)
(Also see "A Visual Trip Through The Psychedelic Pipeline" - Scrip, 8 Mar, 2024.)
(Also see "BMS CDTO Meyers On Gen AI Use Cases, Long-Range Planning Models" - Scrip, 8 Mar, 2024.)